<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of neonatal epilepsy syndromes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of neonatal epilepsy syndromes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of neonatal epilepsy syndromes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Renée Shellhaas, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identifying the cause is a primary clinical objective in the management of neonatal seizures, in part because accurate determination can lead to more precise therapy. Most neonatal seizures are acute symptomatic seizures, but approximately 10 percent are due to epilepsy and have been relabeled by the International League Against Epilepsy (ILAE)  (
         <a class="graphic graphic_table graphicRef91410" href="/z/d/graphic/91410.html" rel="external">
          table 1
         </a>
         ) with the purposes of standardizing terminology and developing a more uniform understanding of the clinical features, diagnosis, and consequences of these disorders [
         <a href="#rid1">
          1-6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14094.html" rel="external">
          "ILAE classification of seizures and epilepsy"
         </a>
         .)
        </p>
        <p>
         This topic review will discuss recognized neonatal epilepsy syndromes. Infantile onset epilepsy syndromes are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes"
         </a>
         .)
        </p>
        <p>
         Importantly, infants with neonatal-onset seizures can have comorbid illnesses that predispose to acute provoked seizures, thereby requiring a search for those causes in all neonates [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6179.html" rel="external">
          "Etiology and prognosis of neonatal seizures"
         </a>
         .)
        </p>
        <p>
         The characterization of distinct types of neonatal seizures and their treatment is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">
          "Clinical features, evaluation, and diagnosis of neonatal seizures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4142659076">
         <span class="h1">
          OVERVIEW OF EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonates with suspected seizures should first be evaluated for immediately treatable, provoked (symptomatic) causes of seizures  (
         <a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76726" href="/z/d/graphic/76726.html" rel="external">
          table 3
         </a>
         ). First-line diagnostic testing includes electroencephalography (EEG) to confirm the diagnosis of seizures and brain magnetic resonance imaging (MRI), which may help narrow the differential diagnosis and tailor the subsequent workup. Serum, urine, and cerebrospinal fluid (CSF) studies are obtained on a case-by-case basis. This evaluation is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">
          "Clinical features, evaluation, and diagnosis of neonatal seizures", section on 'Etiologic evaluation'
         </a>
         .)
        </p>
        <p>
         A complete evaluation for acute provoked seizures (eg, due to hypoxic-ischemic injury, stroke, infection, or metabolic causes) remains necessary even when a familial epilepsy syndrome is suspected. This is critical, since acute provoked seizures are far more common than neonatal epilepsies and require early, effective treatment to mitigate the underlying brain injury and address treatable causes. This is particularly true for seizures associated with metabolic disturbances (eg, hypoglycemia, hypocalcemia, and hypomagnesemia) or central nervous system (CNS) or systemic infections.
        </p>
        <p>
         A therapeutic trial of intravenous
         <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">
          pyridoxine
         </a>
         administration should be performed if seizures are unresponsive to standard treatments. (See
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures", section on 'Pyridoxine or PLP responsive seizures'
         </a>
         and
         <a class="local">
          'PD-DEE and P5PD-DEE'
         </a>
         below.)
        </p>
        <p>
         Genetic testing is recommended in neonates with epilepsy and for those who do not have an acute provoked seizure cause identified on initial history, examination, and neuroimaging [
         <a href="#rid7">
          7
         </a>
         ]. Mandatory newborn screening identifies many treatable causes, but the composition of the screens varies based upon location.
        </p>
        <p>
         Specific investigations for the diagnosis of the neonatal syndromes are discussed in the sections that follow.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SELF-LIMITED (FAMILIAL) NEONATAL SYNDROMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial, now considered "self-limited” epilepsies by the ILAE [
         <a href="#rid6">
          6
         </a>
         ], are syndromes in which there is likely to be spontaneous remission of the seizures, but this is not invariably the case [
         <a href="#rid6">
          6
         </a>
         ]. Depending upon the associated gene, up to 30 percent of individuals will have epilepsy in later life [
         <a href="#rid8">
          8
         </a>
         ]. Although the majority of neonatal seizures occur as acute reactive (provoked) events in response to identifiable etiologic factors  (
         <a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">
          table 2
         </a>
         ), additional rare but distinct neonatal epilepsy syndromes are well recognized  (
         <a class="graphic graphic_table graphicRef91410" href="/z/d/graphic/91410.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Self-limited (familial) neonatal epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Self-limited (familial) neonatal epilepsy (SeLNE) is rare, with an estimated incidence of 5.3 per 100,000 live births [
         <a href="#rid9">
          9
         </a>
         ]. The familial and nonfamilial forms of SeLNE are distinguished by family history; the genetic, clinical, and EEG features are similar.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – SeLNE was previously known by several terms, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benign familial neonatal epilepsy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benign neonatal convulsions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benign idiopathic neonatal seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         "Fifth-day fits" (because of their peak day of onset)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – SeLNE is one of several epilepsies characterized as a channelopathy, caused in most cases by pathogenic variants in voltage-gated potassium channel genes (
         <em>
          KCNQ2
         </em>
         and
         <em>
          KCNQ3
         </em>
         ) [
         <a href="#rid6">
          6,10-21
         </a>
         ]. The nonfamilial form of SeLNE is due to de novo pathogenic variants in these genes. The familial form of the disorder is inherited in an autosomal dominant pattern. The penetrance of these pathogenic variants is approximately 85 percent [
         <a href="#rid22">
          22
         </a>
         ]; 15 percent of those who carry a variant may not have recognized seizures. In addition, there may be some families with undetected variants, or with variants in genes more commonly associated with later-onset seizures or more severe epilepsy syndromes, such as
         <em>
          SCN2A
         </em>
         [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          KCNQ2
         </em>
         variants have also been identified in patients with more severe developmental and epileptic encephalopathy syndromes. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'
         </a>
         and
         <a class="local">
          'KCNQ2-DEE'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Seizures occur within the first seven days of life, with 90 percent occurring between days 4 and 6, and they typically resolve within six weeks to six months, although about 30 percent of individuals with
         <em>
          KCNQ2
         </em>
         -SeLNE develop epilepsy later in life [
         <a href="#rid8">
          8
         </a>
         ]. These seizures occur in term or late preterm infants after an uneventful pregnancy, labor, and delivery, with no family history of seizures (in the case of the nonfamilial form), and with normal neurologic examinations between seizures. The incidence is similar for males and females.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most frequent seizure type is focal tonic, involving the head, face, and limbs [
         <a href="#rid6">
          6
         </a>
         ]. Focal clonic seizures may also occur [
         <a href="#rid7">
          7
         </a>
         ]. Seizures may alternate sides and may progress to bilateral tonic seizures but do not have generalized/bilateral features at onset; associated apnea has sometimes been reported. The seizures are typically brief and last from one to three minutes, though some do evolve into prolonged seizures and the individual seizures may occur in clusters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – SeLNE is a diagnosis of exclusion since the initial clinical presentation may mimic that of infants with acute provoked seizures. Thus, an extensive evaluation for an acute provoked seizure etiology  (
         <a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">
          table 2
         </a>
         ) is necessary even when the suspicion for SeLNE is high. (See
         <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">
          "Clinical features, evaluation, and diagnosis of neonatal seizures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diagnostic criteria  (
         <a class="graphic graphic_table graphicRef139183" href="/z/d/graphic/139183.html" rel="external">
          table 4
         </a>
         ) for SeLNE require focal tonic seizures at onset and a nonlesional brain MRI [
         <a href="#rid6">
          6
         </a>
         ] in an infant delivered after a normal pregnancy and labor. The infant's head circumference and neurologic examination must be normal, and causes of acute provoked seizures must be excluded.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ictal EEG is not distinctive from other electrical or electroclinical seizure types, and an ictal EEG is not required to make the diagnosis [
         <a href="#rid6">
          6
         </a>
         ]. The interictal EEG background can be normal or may be mildly abnormal due to mildly excessive discontinuity (ie, periods of continuous activity alternating with brief, seconds-long periods of suppression) and/or excessive multifocal negative sharp waves.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neuroimaging is mandatory, and a normal MRI is required to confirm the diagnosis of SeLNE. Where available, genetic testing should confirm a pathogenic variant in
         <em>
          KCNQ2
         </em>
         or
         <em>
          KCNQ3
         </em>
         ; lack of variants in these genes suggests a different diagnosis is more likely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The therapy for SeLNE is similar to that for other neonatal seizures, with antiseizure medications acutely administered (see
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures"
         </a>
         ). The diagnosis generally cannot be made until after treatment is initiated, since a full evaluation for sepsis and other more common, and treatable, causes of neonatal seizures is required. If the diagnosis of SeLNE is clear, case reports and case series suggest that
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         (10 mg/kg per day) or
         <a class="drug drug_pediatric" data-topicid="12664" href="/z/d/drug information/12664.html" rel="external">
          oxcarbazepine
         </a>
         (35 mg/kg per day) can be effective treatments [
         <a href="#rid25">
          25
         </a>
         ]. Antiseizure medications can often be stopped once the infant is beyond the usual six-week period of recurrence risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course and outcomes
         </strong>
         – In most cases, seizures abate by age six months, typically by age six weeks. Development is typically normal. Seizures after age six months occur in up to one-third of patients, and those with higher neonatal seizure burden appear to be the most likely to have persistent epilepsy [
         <a href="#rid6">
          6,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Self-limited familial neonatal-infantile epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Self-limited familial neonatal-infantile epilepsy (SeLFNIE) is characterized by focal tonic or focal clonic seizures and no other neurologic abnormalities. The incidence is undetermined [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – SeLFNIE has also been known as benign familial neonatal-infantile seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – SeLFNIE is inherited in an autosomal dominant pattern and is caused by pathogenic variants in the
         <em>
          SCN2A
         </em>
         gene [
         <a href="#rid26">
          26
         </a>
         ]; rare cases are associated with pathogenic variants of the
         <em>
          KCNQ2
         </em>
         gene [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – SeLFNIE is characterized by focal tonic or focal clonic seizures, a family history of neonatal seizures, and no other neurologic abnormalities (normal physical examination and neuroimaging are required). At onset, seizures are focal tonic with head and eye deviation. The seizures typically occur within a few days to several months of life, with a mean onset at 11 weeks (median 13 weeks) [
         <a href="#rid26">
          26
         </a>
         ]. Seizures may last from 20 seconds to 4 minutes, but often occur in clusters [
         <a href="#rid27">
          27
         </a>
         ]. The interictal EEG is typically normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – A complete evaluation for acute provoked seizures  (
         <a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">
          table 2
         </a>
         ) remains necessary even when SeLFNIE is suspected. (See
         <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">
          "Clinical features, evaluation, and diagnosis of neonatal seizures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diagnostic criteria for SeLFNIE  (
         <a class="graphic graphic_table graphicRef139189" href="/z/d/graphic/139189.html" rel="external">
          table 5
         </a>
         ) require the onset, from age 1 day to 21 months, of focal tonic seizures with head and eye deviation, followed by seizures with other tonic and clonic features, which may evolve to bilateral tonic-clonic seizures [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A brain MRI is required to exclude other causes of seizures. The interictal EEG is usually normal. EEG slowing or focal discharges in central and posterior regions may be seen during periods of active seizures [
         <a href="#rid6">
          6,27
         </a>
         ]. However, an ictal EEG is not required to confirm the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Seizures are responsive to treatment with antiseizure medications [
         <a href="#rid6">
          6
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          Carbamazepine
         </a>
         is considered a first-line agent for SeLFNIE [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course and outcomes
         </strong>
         – Seizure frequency is variable (some infants have only a few seizures while others have frequent seizures in clusters), but the seizures cease by 12 to 24 months and do not recur later in life [
         <a href="#rid6">
          6
         </a>
         ], though a subset of patients with early onset
         <em>
          SCN2A
         </em>
         -associated seizures will develop episodic ataxia and may remain on medication treatment [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3453500113">
         <span class="h1">
          DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Developmental and epileptic encephalopathies (DEEs) are severe syndromes associated with refractory seizures and abnormal neurodevelopmental outcomes, which are related to both the underlying syndrome etiology and the seizures or epileptiform abnormalities [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         A severe neonatal epilepsy syndrome should be suspected in newborns who lack an obvious cause for acute seizures, especially if the interictal EEG shows a burst suppression pattern or if the seizures do not respond as expected to initial treatments.
        </p>
        <p class="headingAnchor" id="H2316832238">
         <span class="h2">
          Early infantile DEE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early infantile developmental and epileptic encephalopathy (EIDEE) is reviewed here briefly and discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – EIDEE incorporates the epilepsies previously classified as Ohtahara syndrome and early myoclonic encephalopathy (EME).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and clinical features
         </strong>
         – EIDEE can be caused by a wide range of etiologies. These include developmental brain anomalies (eg, cortical dysplasia and other types of cerebral dysgenesis) as well as genetic syndromes. EIDEE is characterized by onset within the first three months of life, frequent refractory seizures, developmental impairment, and poor prognosis with reduced life expectancy  (
         <a class="graphic graphic_table graphicRef139208" href="/z/d/graphic/139208.html" rel="external">
          table 6
         </a>
         ). Infants with EIDEE may evolve to develop infantile epileptic spasms syndrome (IESS), and then, in childhood, they may develop Lennox-Gastaut syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – This is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment of EIDEE mirrors that of epilepsies in older children, with combinations of antiseizure medications, dietary therapies, and epilepsy surgery in selected infants. Resective epilepsy surgery, in properly selected infants who are referred to highly experienced surgical centers, can be curative [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3667262003">
         <span class="h2">
          KCNQ2-DEE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to self-limited familial neonatal epilepsy, some individuals with de novo missense
         <em>
          KCNQ2
         </em>
         pathogenic variants develop KCNQ2-DEE. Infants with KCNQ2-DEE present in the first week of life with an abnormal neurologic examination (encephalopathy, hypotonia, and lack of visual attentiveness) and severe, treatment-resistant seizures [
         <a href="#rid6">
          6,7,30-33
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – Some infants with KCNQ2-DEE present with what previously was termed Ohtahara syndrome [
         <a href="#rid34">
          34
         </a>
         ]. Current terminology refers to Ohtahara syndrome as an EIDEE. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Seizures typically begin in the first days of life in an infant with encephalopathy and an abnormal neurologic examination [
         <a href="#rid6">
          6
         </a>
         ]. The seizures often have a tonic semiology but are not classically tonic spasms; myoclonic and/or focal seizures are also described, as are sequential seizures. Neonates with gain of function
         <em>
          KCNQ2
         </em>
         variants may have prominent nonepileptic startle-like myoclonus, in addition to encephalopathy and severely abnormal interictal EEG background patterns [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The interictal EEG can have abundant multifocal negative sharp waves and/or can meet criteria for burst suppression. Brain MRI may reveal subtle abnormalities (T1 and T2 hyperintensity) in the basal ganglia and thalami that can resolve after the neonatal period [
         <a href="#rid31">
          31,36
         </a>
         ]. No other specific imaging abnormalities are reported. Genetic testing for
         <em>
          KCNQ2
         </em>
         pathogenic variants is necessary to confirm the diagnosis  (
         <a class="graphic graphic_table graphicRef139220" href="/z/d/graphic/139220.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – While seizures are resistant to treatment, limited data suggest that patients with
         <em>
          KCNQ2
         </em>
         pathogenic variants may respond best to antiseizure medications that act on sodium channels (eg,
         <a class="drug drug_pediatric" data-topicid="12664" href="/z/d/drug information/12664.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          phenytoin
         </a>
         ) [
         <a href="#rid30">
          30,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course and prognosis
         </strong>
         – The seizures resolve within a few months to years in over half of patients, but affected children typically have moderate to severe global neurodevelopmental disabilities [
         <a href="#rid6">
          6,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1399555620">
         <span class="h2">
          PD-DEE and P5PD-DEE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pyridoxine-dependent (ALDH7A1) developmental and epileptic encephalopathy (PD-DEE) and the related disorder, pyridoxamine 5'-phosphate oxidase deficiency (PNPO) developmental and epileptic encephalopathy (P5PD-DEE), are rare but treatable genetic causes of medically refractory neonatal epilepsy. Both syndromes lead to metabolic defects within the lysine degradation pathway. (See
         <a class="medical medical_review" href="/z/d/html/6179.html" rel="external">
          "Etiology and prognosis of neonatal seizures", section on 'Cofactor and vitamin deficiencies'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – PD-DEE is also known as pyridoxine-dependent epilepsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Most patients with PD-DEE or P5PD-DEE develop seizures in-utero or shortly after birth and have co-occurring encephalopathy. However, a later presentation, typically in the first three years of life, is seen in up to one-quarter of patients, with rare patients presenting in adolescence [
         <a href="#rid39">
          39,40
         </a>
         ]. Seizure types are variable, including multifocal myoclonus, focal seizures, epileptic spasms, and generalized tonic-clonic seizures. Seizures may be frequent and evolve to status epilepticus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The interictal EEG is typically markedly abnormal prior to treatment with a burst-suppression pattern and abundant multifocal epileptiform discharges. Brain MRI may be normal or show white matter edema in the setting of severe encephalopathy [
         <a href="#rid39">
          39,41
         </a>
         ]. Other reported MRI abnormalities include ventricular enlargement and corpus callosum hypoplasia. Metabolic testing should not delay treatment, but biochemical evaluation with measurement of urine and plasma alpha-aminoadipic semialdehyde (alpha-AASA) and/or plasma pipecolic acid can aid the diagnosis  (
         <a class="graphic graphic_table graphicRef139221" href="/z/d/graphic/139221.html" rel="external">
          table 8
         </a>
         ). Genetic testing is useful to detect pathogenic variants in the
         <em>
          ALDH7A1
         </em>
         or
         <em>
          PLPB
         </em>
         genes in PD-DEE, or the
         <em>
          PNPO
         </em>
         gene in P5PD-DEE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – In nearly all cases of PD-DEE and P5PD-DEE, seizures respond rapidly to treatment with
         <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">
          pyridoxine
         </a>
         and pyridoxal-5'-phosphate, respectively [
         <a href="#rid6">
          6
         </a>
         ]. Due to the risk for cardiorespiratory collapse, the initial intravenous test doses of pyridoxine should occur in a monitored (hospital) setting. Seizures are unresponsive to antiseizure medications. Treatment is discussed in detail separately. Early initiation of a lysine-restricted diet may result in improved long-term outcomes; L-arginine therapy is also a component of therapy for this syndrome [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">
          "Treatment of neonatal seizures", section on 'Pyridoxine or PLP responsive seizures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course and prognosis
         </strong>
         – Patients can have a normal neurodevelopmental outcome with early, appropriate treatment, but many will experience neurodevelopmental delays.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1693031196">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">
          "Society guideline links: Seizures and epilepsy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H123524714">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for provoked seizures
         </strong>
         – A complete evaluation for acute provoked neonatal seizures (eg, due to hypoxic-ischemic injury, stroke, infection, or metabolic causes) remains necessary even when a self-limited neonatal epilepsy syndrome is suspected. (See
         <a class="local">
          'Overview of evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Self-limited (familial) syndromes
         </strong>
         – Self-limited epilepsies are syndromes in which there is likely to be spontaneous seizure remission, though this is far from inevitable. Although most neonatal seizures occur as acute provoked events in response to identifiable causes  (
         <a class="graphic graphic_table graphicRef73867" href="/z/d/graphic/73867.html" rel="external">
          table 2
         </a>
         ), rare but distinct neonatal epilepsy syndromes are well recognized  (
         <a class="graphic graphic_table graphicRef91410" href="/z/d/graphic/91410.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Self-limited (familial) neonatal epilepsy (SeLNE)
         </strong>
         – SeLNE, once known as "fifth-day fits," is caused in most cases by pathogenic variants in voltage-gated potassium channel genes (
         <em>
          KCNQ2
         </em>
         and
         <em>
          KCNQ3
         </em>
         ). The nonfamilial form of SeLNE is due to de novo pathogenic variants in these genes; the familial form is inherited in an autosomal dominant pattern. Seizures arise in otherwise normal newborn infants within the first seven days of life. The most frequent seizure type is focal tonic, involving the head, face, and limbs. Diagnostic criteria  (
         <a class="graphic graphic_table graphicRef139183" href="/z/d/graphic/139183.html" rel="external">
          table 4
         </a>
         ) for SeLNE require focal tonic seizures at onset and a normal brain MRI. Treatment for SeLNE involves acute administration of antiseizure medications; seizures are typically most responsive to sodium-channel blockers (eg,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         ). Seizures usually resolve within six weeks to six months, but some patients develop persistent epilepsy. Development is typically normal, though some children have learning difficulties and minor motor delays. (See
         <a class="local">
          'Self-limited (familial) neonatal epilepsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Self-limited familial neonatal-infantile epilepsy (SeLFNIE)
         </strong>
         – SeLFNIE is an autosomal dominant epilepsy that is caused in most cases by pathogenic variants in the
         <em>
          SCN2A
         </em>
         gene and characterized by focal tonic or focal clonic seizures and no other neurologic abnormalities. Seizure onset occurs within a few days to several months of life. The diagnosis requires the onset of focal tonic seizures between age one day and 21 months  (
         <a class="graphic graphic_table graphicRef139189" href="/z/d/graphic/139189.html" rel="external">
          table 5
         </a>
         ). Seizures are responsive to pharmacologic treatment, especially sodium channel agents (eg,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         ), and typically remit by age one to two years. (See
         <a class="local">
          'Self-limited familial neonatal-infantile epilepsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Developmental and epileptic encephalopathies (DEEs)
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Early infantile DEE (EIDEE)
         </strong>
         – This syndrome is characterized by early onset, frequent, refractory seizures, developmental impairment, and poor prognosis with reduced life expectancy  (
         <a class="graphic graphic_table graphicRef139208" href="/z/d/graphic/139208.html" rel="external">
          table 6
         </a>
         ). Infants with EIDEE may evolve to develop infantile epileptic spasms syndrome (IESS) and then, in childhood, may develop Lennox-Gastaut syndrome. (See
         <a class="medical medical_review" href="/z/d/html/139238.html" rel="external">
          "Overview of infantile epilepsy syndromes", section on 'Early infantile developmental and epileptic encephalopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          KCNQ2-DEE
         </strong>
         – Infants with KCNQ2-DEE present in the first week of life with neurologic abnormalities (encephalopathy, hypotonia, and lack of visual attentiveness) and severe, treatment-resistant seizures. Seizures resolve within a few months to years in over half of patients, but affected children typically have moderate to severe global neurodevelopmental impairments. Genetic testing for
         <em>
          KCNQ2
         </em>
         pathogenic variants is necessary to confirm the diagnosis  (
         <a class="graphic graphic_table graphicRef139220" href="/z/d/graphic/139220.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'KCNQ2-DEE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PD-DEE and P5PD-DEE
         </strong>
         – Pyridoxine-dependent DEE (PD-DEE) and the related disorder, pyridoxamine 5'-phosphate deficiency DEE (P5PD-DEE), are rare but treatable genetic causes of medically refractory neonatal epilepsy. Metabolic testing should not delay treatment, but biochemical evaluation and genetic testing can aid the diagnosis  (
         <a class="graphic graphic_table graphicRef139221" href="/z/d/graphic/139221.html" rel="external">
          table 8
         </a>
         ). In nearly all cases of PD-DEE and P5PD-DEE, seizures respond rapidly to treatment with
         <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">
          pyridoxine
         </a>
         and pyridoxal-5'-phosphate, respectively. (See
         <a class="local">
          'PD-DEE and P5PD-DEE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1623446850">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dr. Eli Mizrahi, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017; 58:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58:522.
          </a>
         </li>
         <li class="breakAll">
          EpilepsyDiagnosis.org. International League Against Epilepsy. https://www.epilepsydiagnosis.org/ (Accessed on September 10, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: Characteristics of a prospective US cohort. Neurology 2017; 89:893.
          </a>
         </li>
         <li class="breakAll">
          Miceli F, Soldovieri MV, Weckhuysen S, et al. KCNQ2-related disorders. In: GeneReviews®, Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A. (Eds), University of Washington, Seattle (WA) 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symonds JD, Elliott KS, Shetty J, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain 2021; 144:2879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quattlebaum TG. Benign familial convulsions in the neonatal period and early infancy. J Pediatr 1979; 95:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noebels JL. Ion Channelopathies and Heritable Epilepsy. News Physiol Sci 1998; 13:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noebels JL. Modeling human epilepsies in mice. Epilepsia 2001; 42 Suppl 5:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppert M, Singh N. Benign familial neonatal epilepsy with mutations in two potassium channel genes. Curr Opin Neurol 1999; 12:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppert M. Novel K+ channel genes in benign familial neonatal convulsions. Epilepsia 2000; 41:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppert M, Anderson VE, Quattlebaum T, et al. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989; 337:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claes LR, Ceulemans B, Audenaert D, et al. De novo KCNQ2 mutations in patients with benign neonatal seizures. Neurology 2004; 63:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zara F, Specchio N, Striano P, et al. Genetic testing in benign familial epilepsies of the first year of life: clinical and diagnostic significance. Epilepsia 2013; 54:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan SG, Wiznitzer M, Hollman C, et al. Benign familial neonatal convulsions: evidence for clinical and genetic heterogeneity. Ann Neurol 1991; 29:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunniff C, Wiedlin N, Jones KL. Autosomal dominant benign neonatal seizures. Am J Med Genet 1988; 30:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinton BE, Heron SE, Pelekanos JT, et al. Familial neonatal seizures in 36 families: Clinical and genetic features correlate with outcome. Epilepsia 2015; 56:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell KB, McMahon JM, Carvill GL, et al. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology 2015; 85:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia 2016; 57:2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkovic SF, Heron SE, Giordano L, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 2004; 55:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herlenius E, Heron SE, Grinton BE, et al. SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia 2007; 48:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz N, Bast T, Gaily E, et al. Clinical and genetic spectrum of SCN2A-associated episodic ataxia. Eur J Paediatr Neurol 2019; 23:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth J, Constantini S, Ekstein M, et al. Epilepsy surgery in infants up to 3 months of age: Safety, feasibility, and outcomes: A multicenter, multinational study. Epilepsia 2021; 62:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numis AL, Angriman M, Sullivan JE, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology 2014; 82:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012; 71:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen NM, Mannion M, Conroy J, et al. The variable phenotypes of KCNQ-related epilepsy. Epilepsia 2014; 55:e99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet 2016; 2:e96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato M, Yamagata T, Kubota M, et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia 2013; 54:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulkey SB, Ben-Zeev B, Nicolai J, et al. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. Epilepsia 2017; 58:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 2013; 81:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisano T, Numis AL, Heavin SB, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia 2015; 56:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milh M, Boutry-Kryza N, Sutera-Sardo J, et al. Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2. Orphanet J Rare Dis 2013; 8:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiao X, Xue J, Gong P, et al. Clinical and genetic features in pyridoxine-dependent epilepsy: a Chinese cohort study. Dev Med Child Neurol 2020; 62:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasaraghavan R, Parameswaran N, Mathis D, et al. Antiquitin Deficiency with Adolescent Onset Epilepsy: Molecular Diagnosis in a Mother of Affected Offsprings. Neuropediatrics 2018; 49:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills PB, Camuzeaux SS, Footitt EJ, et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 2014; 137:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coughlin CR 2nd, Tseng LA, Abdenur JE, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 2021; 44:178.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6198 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20196795" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276062" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276064" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Instruction manual for the ILAE 2017 operational classification of seizure types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276060" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28276060" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35503712" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733343" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Profile of neonatal epilepsies: Characteristics of a prospective US cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733343" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Profile of neonatal epilepsies: Characteristics of a prospective US cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34687210" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/448564" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Benign familial convulsions in the neonatal period and early infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11390799" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ion Channelopathies and Heritable Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11887961" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Modeling human epilepsies in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10226745" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Benign familial neonatal epilepsy with mutations in two potassium channel genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10961643" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Novel K+ channel genes in benign familial neonatal convulsions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2918897" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Benign familial neonatal convulsions linked to genetic markers on chromosome 20.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9425895" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596769" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : De novo KCNQ2 mutations in patients with benign neonatal seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23360469" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Genetic testing in benign familial epilepsies of the first year of life: clinical and diagnostic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9430594" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A potassium channel mutation in neonatal human epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1859177" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Benign familial neonatal convulsions: evidence for clinical and genetic heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9425900" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3189416" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Autosomal dominant benign neonatal seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25982755" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Familial neonatal seizures in 36 families: Clinical and genetic features correlate with outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26291284" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27888506" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Rapid and safe response to low-dose carbamazepine in neonatal epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15048894" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17386050" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928199" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical and genetic spectrum of SCN2A-associated episodic ataxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34128544" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Epilepsy surgery in infants up to 3 months of age: Safety, feasibility, and outcomes: A multicenter, multinational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24371303" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22275249" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25052858" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The variable phenotypes of KCNQ-related epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27602407" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23621294" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28139826" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24107868" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25880994" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Early and effective treatment of KCNQ2 encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23692823" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31737911" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical and genetic features in pyridoxine-dependent epilepsy: a Chinese cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29401530" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Antiquitin Deficiency with Adolescent Onset Epilepsy: Molecular Diagnosis in a Mother of Affected Offsprings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24645144" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33200442" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due toα-aminoadipic semialdehyde dehydrogenase deficiency.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
